EMA Authorised: Zalasta (olanzapine) — Krka

View source ↗

Summary

Krka-licensed olanzapine (Zalasta) has been authorised in the EU for schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Zalasta (olanzapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Krka. Decision date: 01/03/2024